The nephrotic syndrome is an immunoinflammatory disorder

被引:36
作者
Camici, Marcello [1 ]
机构
[1] Univ Pisa, Dept Internal Med, I-56126 Pisa, Italy
关键词
D O I
10.1016/j.mehy.2006.04.072
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The Nephrotic Syndrome is still a therapeutic and physiopathological challenge. The clinical response to systemic immunosuppression shows that an immunoinflammatory disorder supports the nephrotic syndrome. Experimental (in vitro and in vivo) studies show that proteinuria may induce kidney secretion of proinflammatory and profibrotic cytokines and subsequent renal inflammation mediated by leukocyte recruitment. In turn,the infiltrating teukocytes contribute to renal damage by releasing proinflammatory and profibrotic cytokines (kidney acute remodelling). Chronic proteinuria maintains continuous local cytokine secretion and leukocyte influx into the glomerulus or the interstitial, space (kidney chronic remodelling). In glomerular injury (podocyte injury), proteinuria itself, as well as glomerular secreted cyotokines, stimulates downstream tubular epithelial cells to secrete cytokines, as well. The mutual stimulation between proteinuria-cytokines-podocyte dysfunction-infiltrating leukocytes supports progressive tubular damage, renal fibrosis and glomerulosclerosis. Interfering with the cytokine network by inhibition/blockade of the cytokine receptor and its synthesis (via NFkB and the JAK/STAT intracellular signalling pathway) may represent a promising therapeutic option for systemic immunosuppression. Renal cytokine escape into systemic circulation may provide to hypercytokinemia stress syndrome,which could help to explain the increase in efferent renal sympathetic nerve activity (physiopathological sympathetic overactivity) observed during experimental nephrotic edema. (c) 2006 Published by Elsevier Ltd.
引用
收藏
页码:900 / 905
页数:6
相关论文
共 60 条
[41]   The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes [J].
Parving, HH ;
Lehnert, H ;
Bröchner-Mortensen, J ;
Gomis, R ;
Andersen, S ;
Arner, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :870-878
[42]  
Rangan GK, 1999, KID INT, V6, P116, DOI [10.1046/j.1523-1755.1999.00529.x, DOI 10.1046/J.1523-1755.1999.00529.X]
[43]   Effect of angiotensin II antagonism on the regression of kidney disease in the rat [J].
Remuzzi, A ;
Gagliardini, E ;
Donadoni, C ;
Fassi, A ;
Sangalli, F ;
Lepre, MS ;
Remuzzi, G ;
Benigni, A .
KIDNEY INTERNATIONAL, 2002, 62 (03) :885-894
[44]   How circulating cytokines trigger the neural circuits that control the hypothalamic-pituitary-adrenal axis [J].
Rivest, S .
PSYCHONEUROENDOCRINOLOGY, 2001, 26 (08) :761-788
[45]   Angiotensin II activates nuclear transcription factor κB through AT1 and AT2 in vascular smooth muscle cells -: Molecular mechanisms [J].
Ruiz-Ortega, M ;
Lorenzo, O ;
Rupérez, M ;
König, S ;
Wittig, B ;
Egido, J .
CIRCULATION RESEARCH, 2000, 86 (12) :1266-1272
[46]   Effect of cervical vagotomy on sympathetic nerve responses to peripheral interleukin-1β [J].
Saindon, CS ;
Blecha, F ;
Musch, TI ;
Morgan, DA ;
Fels, RJ ;
Kenney, MJ .
AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2001, 87 (2-3) :243-248
[47]   The pediatric nephrotic syndrome spectrum: Clinical homogeneity and molecular heterogeneity [J].
Schachter, AD .
PEDIATRIC TRANSPLANTATION, 2004, 8 (04) :344-348
[48]   Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance [J].
Szeto, CC ;
Gillespie, KM ;
Mathieson, PW .
IMMUNOLOGY, 2000, 100 (02) :217-224
[49]  
Tang S, 2003, J CLIN INVEST, V111, P515, DOI [10.1172/JCI200316079, 10.1172/JCI16079]
[50]   Type I IgE receptor, interleukin 4 receptor and interleukin 13 polymorphisms in children with nephrotic syndrome [J].
Tenbrock, K ;
Schubert, A ;
Stapenhorst, L ;
Kemper, MJ ;
Gellermann, J ;
Timmermann, K ;
Müller-Wiefel, DE ;
Querfeld, U ;
Hoppe, B ;
Michalk, D .
CLINICAL SCIENCE, 2002, 102 (05) :507-512